For the 2022 financial year, GAAP-reported revenue was $450 million, of which $392 million was attributable to precision oncology testing. There is a … Read source
For the 2022 financial year, GAAP-reported revenue was $450 million, of which $392 million was attributable to precision oncology testing. There is a … Read source